Mitral valve regurgitation (MR) is a backflow of blood that occurs when the heart’s mitral valve fails to close tightly - affecting roughly 2-3% of the global population.

But of the 7.8 million Americans who suffer from it, only around 70,000 opt for mitral repair or replacement surgeries annually due to their inherent high risk.  For everyone else, being forced to live with this potentially chronic condition.

At ValSculpwe believe patients benefit the most of interventional procedures.  Our team specializes in developing advanced suturing systems, made specifically to be used via transcatheter, for the heart.

Our current focus is on a transcatheter technology called SATAR(Segmentally Adjustable Transcatheter Annuloplasty Ring) that aims to replicate and optimize the benefits of a surgical annuloplasty.

SATAR achieves this by delivering a ring composed of interconnected segments that can be inserted as a linear structure.  This design will allow adjustment of the annuloplasty ring configuration to optimize mitral valve leaflet coaptation.

The annuloplasty implant is secured with transcatheter sutures - thus providing outcomes comparable to surgical rings while avoiding invasive anchors. This transcatheter route also reduces and reshapes annulus dilatation to its native size and shape.

To this end, SATAR will not only be as efficient as semi-rigid surgical rings - but also have the ability to address both mitral and tricuspid valve regurgitations.